Monitoring of Serum Her-2/ neu Predicts Response and Progression-Free Survival to Trastuzumab-Based Treatment in Patients with Metastatic Breast Cancer
- 1 March 2004
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (5), 1618-1624
- https://doi.org/10.1158/1078-0432.ccr-0385-3
Abstract
The present pilot study was performed to elucidate whether early changes in serum Her-2/neu extracellular domain (ECD) levels during trastuzumab-based treatment would predict the clinical course of disease in patients with metastatic breast cancer. Sera from 55 patients with Her-2/neu-overexpressing metastatic breast cancer obtained immediately before each weekly administration of trastuzumab were analyzed by a serum Her-2/neu ELISA. Whereas response rates were significantly higher in patients with elevated (>or=15 ng/ml) ECD levels before initiation of treatment (35% versus 7%, P = 0.045), progression-free and overall survival did not differ significantly between patients with normal and elevated ECD levels. In patients responding to treatment, ECD levels decreased significantly as early as from day 8 of treatment onwards (all P for weekly measurements versus baseline <0.001). In contrast, no significant change in ECD levels was observed in patients with progressive disease. Multiple logistic regression analyses identified kinetics of ECD levels as the only factor that allowed for the accurate prediction of response likelihood as early as from day 8 of trastuzumab-based treatment onwards (P = 0.020). In addition, determination of serial ECD levels allowed for the prediction of the risk for disease progression within the observed period as early as day 15 of treatment (P = 0.010). Serial monitoring of the ECD may represent a valuable tool for early prediction of the probability of response and progression-free survival to trastuzumab-based treatment and is thus likely to contribute to an optimization of treatment and resource allocation.Keywords
This publication has 20 references indexed in Scilit:
- Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2–Overexpressing Metastatic Breast CancerJournal of Clinical Oncology, 2002
- Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast CancerJournal of Clinical Oncology, 2002
- Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by HER2 Immunophenotype and Gene AmplificationJournal of Clinical Oncology, 2001
- Clinical Activity of Trastuzumab and Vinorelbine in Women With HER2-Overexpressing Metastatic Breast CancerJournal of Clinical Oncology, 2001
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancerSeminars in Oncology, 2001
- Tissue Expression and Serum Levels of HER-2/neu in Patients with Breast CancerOncology, 1997
- The c-erbB-2 Protein in Oncogenesis: Molecular Structure to Molecular EpidemiologyCritical Reviews™ in Oncogenesis, 1994
- Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteriaInvestigational New Drugs, 1992
- Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu OncogeneScience, 1985